Photo credit: www.investing.com
Class Action Lawsuit Filed Against Caribou Biosciences
New York, New York—On January 5, 2025, Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, announced that a class action lawsuit has been initiated against Caribou Biosciences, Inc. (“Caribou” or “the Company”) (NASDAQ: CRBU) along with certain of its executives.
Class Definition
The lawsuit aims to seek damages for alleged breaches of federal securities laws on behalf of all individuals and organizations that purchased or acquired Caribou securities from July 14, 2023, through July 16, 2024 (the “Class Period”). Investors who believe they may be affected are encouraged to participate in the case by visiting the firm’s website: bgandg.com/CRBU.
Case Details
The Complaint claims that during the Class Period, the Defendants made significantly misleading statements about the Company’s operations and prospects. These claims include accusations that the Defendants inaccurately represented the safety, efficacy, and durability of CB-010 compared to approved autologous CAR-T cell therapies for treating patients with relapsed/refractory B-NHL and/or LBCL. Additionally, the Complaint outlines that Caribou faced substantial risks concerning its financial stability, potentially lacking sufficient cash and capital to support ongoing business operations and preclinical research related to its allogeneic CAR-NK platform. Furthermore, it asserts that these issues could adversely affect Caribou’s overall business trajectory. The Complaint concludes that the Defendants’ public disclosures were misleading throughout this relevant period.
What’s Next?
A class action lawsuit is already underway. Those interested in reviewing the Complaint can access it on the firm’s website: bgandg.com/CRBU. For additional information, individuals may also reach out to Peretz Bronstein, Esq., or Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. Investors who have incurred losses related to Caribou have until February 24, 2025, to request the Court appoint them as lead plaintiff. It is important to note that participating in any recovery does not necessitate serving as the lead plaintiff.
No Financial Risk to Investors
The firm operates on a contingency fee basis, meaning there are no upfront costs for representation in class actions. If successful, the firm seeks reimbursement for expenses and attorneys’ fees, typically as a percentage of the total recovery.
Why Choose Bronstein, Gewirtz & Grossman?
Bronstein, Gewirtz & Grossman, LLC is recognized nationally for representing investors in securities fraud class actions and shareholder derivative lawsuits. The firm has a track record of recovering hundreds of millions of dollars for investors across the nation.
For the original source of this announcement, visit Newsfile Corp.
Source
www.investing.com